ImmunityBio COVID-19 vaccine
{{Short description|Viral vector COVID-19 vaccine}}
{{Use dmy dates|date=September 2020}}
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.{{Cite web|title=SA's Biovac to team up with US based ImmunityBio in making its vaccine|url=https://www.businessinsider.co.za/sas-biovac-to-team-up-with-us-based-immunitybio-in-making-its-vaccine-2021-3|access-date=2021-03-23|website=BusinessInsider}}{{Cite web|title=ImmunityBio Inc: hAd5-Covid-19 – COVID19 Vaccine Tracker|url=https://covid19.trackvaccines.org/vaccines/49/|access-date=2021-03-23|website=covid19.trackvaccines.org}}
{{Infobox drug
| drug_name = ImmunityBio
| type = vaccine
| image =
| alt =
| caption =
| vaccine_type = viral
| target = SARS-CoV-2
| pronounce =
| tradename = hAd5
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_NZ =
| legal_US =
| legal_UN =
| legal_status =
| CAS_number = 2698362-05-7
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| synonyms =
}}
Manufacturing
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines. The contract with America-based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa
ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.{{Cite web| vauthors = Fisher S |title=Nzimande excited about vaccine partnership between Biovac & ImmunityBio|url=https://ewn.co.za/2021/03/18/nzimande-announces-manufacturing-partnership-between-sa-s-biovac-and-us-firm-immunitybio|access-date=2021-03-20|website=ewn.co.za|language=en}}{{Cite web| vauthors = Sguazzin A |title=SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says|url=https://www.news24.com/fin24/companies/health/sas-biovac-to-use-deal-with-us-based-immunitybio-to-boost-local-vaccine-creation-ceo-says-20210320|access-date=2021-03-20|website=Fin24|language=en-US}}
History
In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.{{cite journal| vauthors = Cross R |date=12 May 2020|title=Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past?|url=https://cen.acs.org/pharmaceuticals/vaccines/Adenoviral-vectors-new-COVID-19/98/i19|journal=Chemical & Engineering News|volume=98|issue=19}}
On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials.{{cite news| vauthors = Cohen J |date=1 June 2020|title=Operation Warp Speed selects billionaire scientist's COVID-19 vaccine for monkey tests|publisher=American Association for the Advancement of Science|agency=Science (magazine)|url=https://www.science.org/content/article/operation-warp-speed-selects-billionaire-scientist-s-covid-19-vaccine-monkey-tests}} The company "hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020."
= Clinical trials =
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.{{Cite news|date=2021-03-19|title=Covid-19 to Serve as Platform for South African Vaccine Industry|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2021-03-19/immunitybio-to-have-covid-19-vaccine-made-in-south-africa|access-date=2021-03-20}}{{Cite web|date=2021-01-19|title=ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread|url=https://www.businesswire.com/news/home/20210119005426/en/%C2%A0ImmunityBio-Announces-Phase-I-Trial-of-COVID-19-Vaccine-Candidate-in-South-Africa-as-New-Variants-of-SARS-CoV-2-Spread|access-date=2021-03-23|website=www.businesswire.com|language=en}}{{Cite web| vauthors = Sguazzin A |title=SA's BioVac to use deal with US-based ImmunityBio to boost local vaccine creation, CEO says|url=https://www.news24.com/fin24/Companies/Health/sas-biovac-to-use-deal-with-us-based-immunitybio-to-boost-local-vaccine-creation-ceo-says-20210320|access-date=2021-03-23|website=Fin24|language=en-US}}{{update-inline|date=June 2022}}
References
{{reflist}}
External links
{{scholia}}
{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}
{{DEFAULTSORT:Immunitybio Covid-19 Vaccine}}
Category:Clinical trials related to COVID-19
Category:American COVID-19 vaccines